Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Shionogi Chief Eyes Conditional Approval for COVID-19 Vaccine, Supply by Year’s End If OK’ed
May 11, 2021
- Chugai, Japan Govt Cut Supply Deal for COVID-19 Antibody Cocktail
May 11, 2021
- Takeda Submits Positive Japan Data for Approval-Pending Moderna Vaccine
May 11, 2021
- Shionogi Incurs Double-Digit Sales Fall in FY2020 as Infectious Disease Meds Falter
May 11, 2021
- Daiichi Sankyo’s DS-1062 Notches Positive PI Data in Triple Negative Breast Cancer
May 11, 2021
- Lawyer Hiroaki Tanaka Tapped to Lead Kobayashi Kako in Management Reshuffle
May 11, 2021
- Maruishi to Curb Supply of 5 Sedative Products due to Increase in Severe COVID-19 Cases
May 11, 2021
- Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line
May 10, 2021
- Kyoto Startup to Begin Clinical Trial of iPSC-Derived Platelet Agent This Year, Eyes 10 Billion Yen Biz
May 10, 2021
- Kyowa Kirin’s Q1 Sales Rise on Strong Performance Overseas
May 10, 2021
- Positive Ruling for Shionogi Now Final and Binding: Osaka Tax Suit
May 10, 2021
- Astellas’ Xtandi Earns European Approval for HSPC
May 10, 2021
- Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players
April 30, 2021
- Shionogi, InveniAI Ink Drug Discovery Collaboration
April 30, 2021
- 300 Million Yen Fine Sought for Toho Too, Court Decision Due June 2: Bid-Rigging Trial
April 30, 2021
- Takeda’s Mobocertinib Gets FDA’s Priority Review for EGFR Exon 20-Mutant NSCLC
April 30, 2021
- Pfizer Japan Posts 251 Billion Yen Sales in FY2020 after Upjohn Spinoff
April 30, 2021
- Amgen Files KRAS Inhibitor Sotorasib in Japan for NSCLC
April 30, 2021
- Court’s Settlement Offer on Opdivo Royalty Dispute Fails
April 28, 2021
- Prosecutors Seek 300 Million Yen Fine for Suzuken, Jail Terms for Employees: Bid-Rigging Trial
April 28, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…